Landmark analysis of cumulative incidence of NRM, relapse, and cGVHD after day 80 of aGVHD treatment initiation. NRM (A), relapse (B), and cGVHD (C). The 2-year NRM in the SS, SD, and SR groups were 19% (95% CI, 11-27), 20% (95% CI, 12-29), and 40% (95% CI, 29-50), respectively. The 2-year relapse risk in the SS, SD, and SR groups were 22% (95% CI, 13-31), 28% (95% CI, 18-37), and 23% (95% CI, 14-31), respectively. The 2-year incidence of cGVHD in the SS, SD, and SR groups were 29% (95% CI, 20-38), 46% (95% CI, 35-57), and 41% (95% CI, 31-51), respectively.